Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Description

The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines

Conditions

Chemotherapy Induced Nausea and Vomiting

Study Overview

Study Details

Study overview

The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines

Akynzeo or Olanzapine for Patients Who Experience Breakthrough CINV in Patient Receiving Moderately or Highly Emetogenic Chemotherapy After First Cycle of Chemotherapy

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Condition
Chemotherapy Induced Nausea and Vomiting
Intervention / Treatment

-

Contacts and Locations

Mount Olive

Rudolph M Navari, Mount Olive, Alabama, United States, 35117

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * CHEMOTHERAPY NAIIVE
  • * patient receiving moderately or highly emetogenic chemotherapy
  • * lung cancer
  • * breast cancer
  • * PRIOR CHEMOTHERAPY for any cancer
  • * nausea or vomiting 24 hours prior to study entry

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Simon Williamson Clinic,

Study Record Dates

2023-12-31